Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Who are BioCrysts partners?

April 26, 2017biocryst partners

0

Posted

Who are BioCrysts partners?

1 Answer

0

Posted

We currently have partnerships for our three drug candidates in clinical trials. Below is a summary of these partnerships. • Mundipharma International Holdings, Ltd. for the development and commercialization of Fodosine™ in Europe, Asia, Australia and certain neighboring countries • Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan and Korea, respectively. In January 2007, the U.S. Department of Health and Human Services awarded the Company a $102.6 million, four year contract for the advanced development of peramivir. Funding from the contract will support manufacturing of clinical lots, process validation, clinical studies and other U.S. product approval requirements. BioCryst currently has collaborations with leading academic organizations including The University of Alabama at Birmingham, Emory University, Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd., New Zealand.